Application of tumor-like single-leaf rutin in preparation of product for reducing accumulation of advanced glycosylation end products

Abstract

The invention discloses an application of tumor-like single-leaf rutin in preparation of a product for reducing accumulation of advanced glycosylation end products, and belongs to the technical field of cosmetics and functional foods. The tumor-like single-leaf rutin can effectively reduce AGEs accumulation caused by bad diet and bad lifestyles (staying up late and smoking), improve skin darkness and yellowing, and relieve and relieve skin injury and skin aging caused by skin saccharification, has anti-saccharification and anti-aging effects, and can be used for anti-saccharification and anti-aging products.

Description

Technical Field

[0001] The present application relates to the technical field of cosmetics and functional foods, and in particular to the application of rutin in the preparation of products for reducing the accumulation of advanced glycation end products. Background Art

[0002] Glycation refers to the process of non-enzymatic binding of sugar molecules (such as glucose) to biological macromolecules such as proteins and fats. With age or long-term high-sugar diet, glycation reactions accelerate, leading to the production of advanced glycation end products (AGEs). AGEs accumulate in the body, causing damage to cells and tissues, increasing oxidative stress and inflammatory responses, leading to a variety of chronic diseases such as diabetes, cardiovascular disease, and neurodegenerative diseases. The production of AGEs is also related to skin aging, deepening of wrinkles, and other problems. Skin cells, skin proteins, and skin collagen fibers are prone to glycation reactions under the conditions of free radicals generated by harsh environments, pollution, and sun exposure, causing the skin to lose its normal function and become dull and dull, with deepening wrinkles. Therefore, anti-glycation is also an important way to delay skin aging.

[0003] As people pay more and more attention to health and anti-aging, the market demand for high-efficiency anti-glycation products is growing rapidly. Anti-glycation has been proven to be related to anti-aging and the prevention of various diseases. Polyphenol compounds have been proven to have antioxidant, AGEs formation inhibition, metal chelation, protein interaction, methylglyoxal capture, AGEs receptor blocking and other functions. In the existing technology, polyphenol compounds are mostly used for anti-glycation, but their effect of reducing AGEs accumulation is limited, and it is impossible to obtain satisfactory anti-glycation and anti-aging effects at the same time. Summary of the invention

[0004] Based on this, the main purpose of this application is to provide the use of rutin in the preparation of products that reduce the accumulation of advanced glycation end products. Rutin can effectively reduce the accumulation of AGEs caused by poor diet and unhealthy lifestyle (staying up late, smoking), and has anti-glycation and anti-aging effects.

[0005] In a first aspect of the present application, a use of rutin in the preparation of a product for reducing the accumulation of advanced glycation end products is provided.

[0006] In some embodiments, the product that reduces accumulation of advanced glycation end products comprises an anti-glycation and / or anti-aging product.

[0007] In some embodiments, the product that reduces accumulation of advanced glycation end products is a product that inhibits the production of advanced glycation end products.

[0008] In some embodiments, the product for reducing the accumulation of advanced glycation end products is a product for reducing the generation of AGEs in a BSA-MGO reaction system.

[0009] In some embodiments, the product that reduces the accumulation of advanced glycation end products is a product that inhibits the generation of AGEs during glucose-induced increase in cellular AGEs.

[0010] In some embodiments, the product for reducing the accumulation of advanced glycation end products is a product for reducing skin yellowing caused by the accumulation of AGEs.

[0011] In some embodiments, the product that reduces the accumulation of advanced glycation end products is a product that exerts an anti-aging effect by reducing AGEs.

[0012] In some embodiments, the product for reducing accumulation of advanced glycation end products comprises at least one of a cosmetic and a food.

[0013] In some embodiments, the product is used orally or topically.

[0014] In some embodiments, the dosage form of the product includes solid dosage form, semisolid dosage form and liquid dosage form; preferably, the dosage form of the product is a liquid dosage form.

[0015] In some embodiments, the liquid dosage form includes a solution, a syrup, an emulsion or a tincture; the solid dosage form includes a tablet, a capsule, a pill or a granule; the semisolid dosage form includes an ointment, a gel paste or a patch; the liquid dosage form includes a solution, a syrup, an emulsion or a tincture.

[0016] In a second aspect, the present application provides a product for reducing the accumulation of advanced glycation end products, including rutin.

[0017] In some embodiments, the product for reducing accumulation of advanced glycation end products further comprises an excipient.

[0018] In a third aspect, the present application provides an anti-glycation and / or anti-aging product, comprising rutin.

[0019] In some embodiments, the anti-glycation and / or anti-aging product further comprises auxiliary materials.

[0020] Compared with the prior art, this application has the following beneficial effects:

[0021] 1. Rutin can effectively reduce the accumulation of AGEs caused by poor diet and unhealthy lifestyle (staying up late, smoking), improve dull and yellow skin, and relieve and reduce skin damage and skin aging caused by skin glycation.

[0022] 2. Rutin can not only reduce the production of AGEs in the BSA-MGO pure in vitro AGEs production model (the AGEs inhibition effect is better than aminoguanidine), but also effectively reduce the AGEs level in the glucose-induced intracellular AGEs production model.

[0023] 3. Rutin can reduce wrinkles and has significant anti-aging effects.

[0024] 4. Rutin has no toxic effect on cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the technical solutions in the embodiments of the present application or the prior art, the following briefly introduces the drawings required for use in the embodiments or the prior art description. The drawings are only used to illustrate the preferred implementation methods and are not considered to be limitations of the present application. The same reference symbols are used throughout the drawings to represent the same components. In the drawings:

[0026] Figure 1 The results show the inhibition rate of different substances on AGEs. DETAILED DESCRIPTION

[0027] In order to make the purpose, technical solution and advantages of this application clearer and to provide a more thorough and comprehensive understanding of the disclosed content of this application, the technical solution of this application will be clearly and completely described below in conjunction with the specific embodiments of this application and the corresponding drawings. The described embodiments are only part of the embodiments of this application, not all of them.

[0028] The implementation of the present application is described in detail below in conjunction with the accompanying drawings. This embodiment is implemented based on the technical solution of the present application, and a detailed implementation method and specific operation process are given, but the protection scope of the present application is not limited to the following embodiments.

[0029] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.

[0030] the term

[0031] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:

[0032] In the present application, "multiple", "multiple", "at least one" and the like, unless otherwise specified, refer to a number greater than or equal to 2. For example, "one or more" or "at least one" means one or greater than or equal to two.

[0033] In the present application, the terms "preferable", "particularly", etc. are used for descriptive purposes to indicate differences in content, but should not be construed as limiting the scope of protection of the present application.

[0034] In the present application, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.

[0035] In a first aspect of the present application, a use of rutin in the preparation of a product for reducing the accumulation of advanced glycation end products is provided.

[0036] Tuberculatin is called Tuberculatin in English, with a CAS number of 90706-10-8. Its structure is as follows:

[0037] .

[0038] Rutin is a lignin monomer with antiviral effects. In this application, after experimental verification, it was found that Rutin can effectively reduce the accumulation of AGEs caused by poor diet and unhealthy lifestyle (staying up late, smoking), improve skin dullness and yellowing, relieve and reduce skin damage and skin aging caused by skin glycation, and has anti-glycation and anti-aging effects.

[0039] Furthermore, rutin can not only reduce AGEs production in the BSA-MGO pure in vitro AGEs production model, but also effectively reduce AGEs levels in the glucose-induced intracellular AGEs production model without any toxic effects on cells.

[0040] In some embodiments, the product that reduces accumulation of advanced glycation end products comprises an anti-glycation and / or anti-aging product.

[0041] In some embodiments, the product that reduces accumulation of advanced glycation end products is a product that inhibits the production of advanced glycation end products.

[0042] In some embodiments, the product for reducing the accumulation of advanced glycation end products is a product for reducing the generation of AGEs in a BSA-MGO reaction system.

[0043] In some embodiments, the product that reduces the accumulation of advanced glycation end products is a product that inhibits the generation of AGEs during glucose-induced increase in cellular AGEs.

[0044] In some embodiments, the product for reducing the accumulation of advanced glycation end products is a product for reducing skin yellowing caused by the accumulation of AGEs.

[0045] In some embodiments, the product that reduces the accumulation of advanced glycation end products is a product that exerts an anti-aging effect by reducing AGEs.

[0046] In some embodiments, the product for reducing accumulation of advanced glycation end products comprises at least one of a cosmetic and a food.

[0047] It can be understood that the cosmetics may include cleaning cosmetics (such as facial cleansers, shampoos, and shower gels) and care cosmetics (such as lotions and skin lotions); the cosmetics can be divided into aqueous preparations (such as perfumes and lotions), oil preparations (such as makeup remover oils, massage oils, and hair oils), emulsions (such as cleansing creams, moisturizing creams, and skin lotions), gel products (such as cleansing gels and sleeping masks), paste products (such as shampoo creams and paste masks), etc.

[0048] It is understandable that the product for reducing accumulation of advanced glycation end products can be administered in any form without special requirements. In some embodiments, the use of the product includes oral administration or external use.

[0049] It is understandable that there is no special requirement for the dosage form of the product for reducing accumulation of advanced glycation end products. In some embodiments, the dosage form of the product includes a solid dosage form, a semi-solid dosage form and a liquid dosage form; preferably, the dosage form of the product is a liquid dosage form.

[0050] In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oil, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or a mixture of these substances. In addition to these inert diluents, the composition may also contain adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents and spices. For example, a suspension may contain a suspending agent, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and dehydrated sorbitan esters, microcrystalline cellulose, aluminum methylate and agar or a mixture of these substances.

[0051] In some embodiments, the solid dosage form includes tablets, capsules, pills or granules; the semisolid dosage form includes ointments, gel pastes or patches; the liquid dosage form includes solutions, syrups, emulsions or tinctures.

[0052] In addition to the active compound, the solid dosage form may contain conventional inert excipients (or carriers), such as sodium citrate or dicalcium phosphate, or: (a) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, such as hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and acacia; (c) humectants, such as glycerol; (d) disintegrators, such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, such as paraffin; (f) absorption accelerators, such as quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glyceryl monostearate; (h) adsorbents, such as kaolin; and (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage form may also contain a buffer. Solid dosage forms such as tablets, pills, capsules, pills or granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifiers, and the release of the active compound or compounds in such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can also be formed into microcapsules with one or more of the above-mentioned excipients.

[0053] In addition to active compounds, semisolid dosage forms may include conventional matrices and excipients. Depending on the specific dosage form, the corresponding matrix or excipient can be selected. For example, common matrices for ointments include vaseline, lard, lanolin, etc., and common matrices and excipients for pastes include glycerin, liquid paraffin, etc.; other active ingredients can be appropriately added to extracts; common matrices for licking preparations include starch, syrup, vegetable oil, etc.

[0054] In some embodiments, the product is an oral liquid dosage form. It is understandable that the oral liquid dosage form includes oral solutions, oral suspensions, oral emulsions, etc.

[0055] In some embodiments, the product is a liquid dosage form for external use and can be applied by spraying, spreading, etc.

[0056] In a second aspect, the present application provides a product for reducing the accumulation of advanced glycation end products, including rutin.

[0057] In some embodiments, the product for reducing accumulation of advanced glycation end products further comprises an excipient.

[0058] In a third aspect, the present application provides an anti-glycation and / or anti-aging product, comprising rutin.

[0059] In some embodiments, the anti-glycation and / or anti-aging product further comprises auxiliary materials.

[0060] It can be understood that Rutin has both anti-glycation and anti-aging effects and can be used in anti-glycation and / or anti-aging products.

[0061] It is understandable that the nodular simple leaf rutin can be added with auxiliary materials to prepare different dosage forms. The auxiliary materials can specifically include carriers, fillers, diluents, excipients, solvents, functional additives, coating materials or encapsulation materials, etc.

[0062] Unless otherwise specified, the raw materials used in the following experiments can be purchased from the market.

[0063] The following are specific embodiments.

[0064] Examples 1-3

[0065] Effects of different anti-glycation and anti-aging substances on the production of AGEs in the BSA-MGO model.

[0066] Conventional AGEs have fluorescent properties. This experimental example uses the principle that methyl glycol and bovine serum albumin undergo glycation reaction in vitro to form AGEs for modeling. After adding anti-glycation and anti-aging substances, the AGE inhibition rate is calculated by the fluorescent quantitative method to evaluate its anti-glycation effect.

[0067] 1. Test materials and instruments

[0068] 1.1 Test reagents

[0069] Bovine serum albumin (BSA), methylglyoxal (MGO), glucose: analytical grade, Sigma, USA.

[0070] 1.2 Test samples

[0071] Anti-glycation and anti-aging substances: Tuberculatin, CAS#: 90706-10-8; Aminoguanidine, CAS#: 1937-19-5.

[0072] 1.3 Test equipment

[0073] Microplate reader (Synergy H1), Bio-Tek, USA.

[0074] 2. Test methods

[0075] 2.1 Establishment of in vitro protein AGE formation system

[0076] BSA (bovine serum albumin) and MGO (methylglyoxal) were prepared into 10 mg / ml and 25 mM reaction solutions, respectively, and the solvent was phosphate buffer (10 mM, pH 7.4) to form a BSA-MGO reaction system as a model group for AGEs generation. The OD value of the formed AGEs was measured by a microplate reader (Synergy H1, Bio-Tek) (detection wavelength 370 nm, reference wavelength 440 nm).

[0077] 2.2 Determination of inhibition of AGE formation in vitro

[0078] The mixed incubation solutions prepared in Examples 1-3 and Comparative Examples 1-2 were prepared with liquids containing 10 mg / ml BSA and 25 mM MGO. The control group (blank example) was a BSA-MGO reaction system without the test substance. The above liquids were sterile filtered with a 0.2 μm filter membrane and dispensed into 1.5 mL conical bottom centrifuge tubes.

[0079] Table 1: Contents of anti-glycation and anti-aging substances in different embodiments and comparative examples

[0080]

[0081] Then 100 μl of the reaction solution was placed in a black 96-well ELISA plate to detect the fluorescence value on day 0. The OD value of the formed AGEs was measured by an ELISA reader (Synergy H1, Bio-Tek) (detection wavelength 370 nm, reference wavelength 440 nm).

[0082] The remaining reaction solution was placed in a 37°C incubator for 4 days, and 100 μl of the reaction solution was placed in a black 96-well ELISA plate on the 4th day to detect the fluorescence value on the 4th day. The OD value of the formed AGEs was measured by an ELISA reader (Synergy H1, Bio-Tek) (detection wavelength 370 nm, reference wavelength 440 nm).

[0083] 2.3 Data processing and statistical analysis methods (each group of experiments was repeated at least 3 times)

[0084] The AGE inhibition rate was calculated using the formula;

[0085] AGE inhibition rate = (CT) / C × 100%;

[0086] Among them, C is the fluorescence intensity of the control group (blank case), that is, the fluorescence intensity of the BSA-MGO reaction system in the absence of anti-glycation and anti-aging substances; T is the fluorescence intensity of the BSA-MGO reaction system in the presence of anti-glycation and anti-aging substances.

[0087] 3. Test results

[0088] The inhibitory effect of the test samples on AGEs, such as Figure 1 And as shown in Table 2.

[0089] Table 2: AGE inhibition rates in Examples 1-3, Comparative Examples 1-2 and Blank Examples

[0090]

[0091] Through Figure 1 The results in Table 2 were used to compare the AGEs inhibition rate. It was found that the AGEs inhibition rate of aminoguanidine at 1mM was 15.51%, and the AGEs inhibition rate at 10mM was 53.11%. As the concentration of Tuberculatin increased at 1μM, 3μM, and 10μM, the AGEs inhibition rate gradually increased in a concentration-dependent manner, which were 20.96%, 26.69%, and 56.35%, respectively. The AGEs inhibition effect was higher than that of 1mM aminoguanidine. Moreover, when the drug concentration of Tuberculatin was higher than 10μM, the AGEs inhibition effect was higher than that of 10mM aminoguanidine. The above results prove that in the in vitro BSA-MGO system, Tuberculatin can significantly inhibit the generation of AGEs, and this inhibition is concentration-dependent.

[0092] Embodiment 4-6

[0093] Effects of different glucose concentrations on the levels of AGEs in HaCaT cells.

[0094] 1. Test materials and instruments

[0095] 1.1 Test reagents

[0096] Human keratinocytes (HaCaT) cells, glucose: analytical grade, Sigma, USA. BCA (bicinchoninic acid) protein assay kit: Bio-Tech Biotechnology Co., Ltd. Human advanced glycation end products (AGEs) enzyme-linked immunosorbent assay kit: Wuhan Huamei Biotechnology.

[0097] 1.2 Test equipment

[0098] Microplate reader (Synergy H1), Bio-Tek, USA.

[0099] 2. Test methods

[0100] 2.1 Construction of cell glycosylation model

[0101] This application uses glucose (D-Glucose) (MCE, HY-B0389, purity: ≥98.0%) as an inducer for the construction of a human keratinocyte (HaCaT) cell saccharification model. The cells are grown to the logarithmic growth phase and plated so that the confluence of the cells in the 6 cm dish reaches 60% on the second day.

[0102] 2.2 Effects of different glucose concentrations on HaCaT cell viability

[0103] HaCaT was inoculated in a 96-well plate, and 100 μl of a suspension at a concentration of 1.5×105 / ml was added to each well and cultured until the next day. The drug was diluted with culture medium to obtain Examples 4-6 and blanks as shown in Table 3, so that the final concentrations of glucose were 100 mM, 150 mM, and 200 mM, respectively. After the liquid was replaced, the culture was continued for 24 hours. 10 μl CellCounting Kit-8 (CCK-8, Dojindo) was added to each well of the 96-well plate and cultured for 1~ 2 hours. The OD value was detected at 450 nm using an enzyme microplate reader, and the cell viability data are shown in Table 4. CCK8 is a kit based on WST-8 and widely used for rapid and highly sensitive detection of cell proliferation and cytotoxicity. WST-8 can be reduced by some dehydrogenases in mitochondria to generate orange-yellow formazan in the presence of an electron coupling agent. The more and faster the cell proliferation, the darker the color; the greater the cytotoxicity, the lighter the color. For the same cells, the depth of color is linearly related to the number of cells.

[0104] Table 3: Glucose content in different embodiments

[0105]

[0106] Table 4: Cell viability in Examples 4-6 and blank examples

[0107]

[0108] 2.3 Effects of different glucose concentrations on AGE levels in HaCaT cells

[0109] The drug was diluted with complete medium (10% FBS (Gibco) + DMEM (Gibco)) to obtain Examples 4-6 and blank examples as shown in Table 3, so that the final concentrations of glucose were 100 mM, 150 mM, and 200 mM, respectively. After incubating the cells for 48 hours, the cell samples were collected for BCA and intracellular AGEs content determination, and the AGEs content per unit protein was calculated.

[0110] The OD value of the formed AGEs was measured by a microplate reader (Synergy H1, Bio-Tek) (detection wavelength 370 nm, reference wavelength 440 nm). BCA (bicinchoninic acid) was measured using the known technology in the art. Under alkaline conditions, divalent copper ions can be reduced to monovalent copper ions by proteins. The monovalent copper ions interact with the unique BCA Solution A to produce a sensitive color reaction. The water-soluble complex shows strong absorbance at 562nm, and the absorbance and protein concentration have a good linear relationship in a wide range. Therefore, the protein concentration can be calculated based on the absorbance value. The test results are shown in Table 5.

[0111] Table 5: Effects of different examples on AGEs levels in HaCaT cells

[0112]

[0113] According to the results of cell viability detection (Section 2.2) and microscopic observation, when the glucose concentration reached 200 mM, the cells showed obvious cell death. Combined with Table 5, it can be seen that when the final glucose concentration reached 150 mM, the AGEs level increased to 1.45 times the normal level. Therefore, 150 mM glucose can be used as the induction condition of the cell glycation model.

[0114] Embodiment 7-9

[0115] Tuberculatin can reduce the production of intracellular AGEs in a glucose-induced cellular glycation model.

[0116] 1. Test materials and instruments

[0117] 1.1 Test reagents

[0118] Human keratinocytes (HaCaT) cells, glucose: analytical grade, Sigma, USA. BCA (bicinchoninic acid) protein assay kit: Bio-Tech Biotechnology Co., Ltd. Human advanced glycation end products (AGEs) enzyme-linked immunosorbent assay kit: Wuhan Huamei Biotechnology.

[0119] 1.2 Test equipment

[0120] Microplate reader (Synergy H1), Bio-Tek, USA.

[0121] 2. Test methods

[0122] 2.1 Construction of cell glycosylation model

[0123] This application uses glucose (D-Glucose) (MCE, HY-B0389, purity: ≥98.0%) as an inducer for the construction of a human keratinocyte (HaCaT) cell saccharification model. The cells are grown to the logarithmic growth phase and plated so that the confluence of the cells in the 6 cm dish reaches 60% on the second day.

[0124] 2.2 Effect of Tuberculatin on HaCaT cell viability

[0125] HaCaT was inoculated into a 96-well plate at a concentration of 1.5 × 10 5 / ml suspension 100μl, culture until the next day, add complete culture medium containing 0.4μM, 2μM, 10μM Tuberculatin and continue to culture for 24h, add 10μl Cell Counting Kit-8 (CCK-8, Dojindo) to each well of 96-well plate and culture for 1~2h, and detect OD value at 450nm with enzyme microplate reader. The results are shown in Table 6.

[0126] Table 6: Cell viability in different concentrations of Tuberculatin and blank samples

[0127]

[0128] 2.3 Effects of different glucose concentrations on AGE levels in HaCaT cells

[0129] The drug was diluted with complete medium (10% FBS (Gibco) + DMEM (Gibco)) to obtain Examples 7-9 and blanks as shown in Table 7, so that the final concentration of glucose was 150 mM, and the final concentrations of rutin were 0.4 μM, 2 μM, and 10 μM, respectively. After incubating the cells for 48 hours, the cell samples were collected for BCA and intracellular AGEs content determination, and the AGEs content per unit protein was calculated.

[0130] The OD value of the formed AGEs was measured by a microplate reader (Synergy H1, Bio-Tek) (detection wavelength 370 nm, reference wavelength 440 nm), and the results are shown in Table 8.

[0131] Table 7: Contents of glucose and Tuberculatin in different embodiments

[0132]

[0133] Table 8: Effects of different examples on AGEs levels in HaCaT cells

[0134]

[0135] As shown in Table 8, after treatment with 150 mM glucose, the level of intracellular AGEs in the comparative example increased to 1.34 times that of the blank example (control group). When glucose and Tuberculatin were treated simultaneously, the level of intracellular AGEs was significantly reduced compared with the group treated with glucose only. When the concentration of Tuberculatin was 10 μM, the intracellular AGEs was only 0.72 times that of the blank example, indicating that Tuberculatin has a highly effective AGEs inhibition effect. When Tuberculatin is used in the preparation of anti-glycation foods and anti-glycation health products, especially in the specific application of beauty products, the effective concentration of Tuberculatin is recommended to refer to the data recorded in the above examples.

[0136] Examples 10-12

[0137] Anti-aging efficacy test of aqueous solution prepared with anti-glycation and anti-aging substances

[0138] Subjects: 40 subjects were divided into 4 groups, 10 in each group, aged 30-50 years old. All subjects had dark yellow skin, wrinkles, decreased collagen fiber elasticity, dark brown spots and other phenomena. The subjects were in good health, had no history of skin diseases and allergies, had non-sensitive skin, and were able to use skin care products according to specifications. Each group of subjects sprayed their faces with a solution containing 0μM, 0.4μM, 2μM, and 10μM Tuberculatin every morning and evening (sprayed about 20 cm from the face, sprayed on the face in a Z shape 3 times), once a day in the morning and evening, for 3 consecutive months, and compared the skin conditions before and after 3 months, and calculated the wrinkle reduction rate of each group of subjects. The test results are shown in Table 9. The VISIA-CR facial skin image analyzer was used to test the improvement of wrinkles, observe the wrinkle depth analysis of the skin, the wrinkle reduction rate, and measure the change rate before and after 3 months.

[0139] Table 9: Experimental data of the trial effect of aqueous solution containing Tuberculatin

[0140]

[0141] It can be seen from the test results that Examples 10-12 can reduce wrinkles, and the wrinkle reduction rate is positively correlated with the dosage of Tuberculatin. Among them, Example 12 has the best effect, indicating that Tuberculatin has a significant anti-aging effect.

[0142] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0143] The above-mentioned embodiments only express several implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present application, and these all belong to the protection scope of the present application. Therefore, the protection scope of the patent of the present application shall be subject to the attached claims.

Claims

1. Application of rutin in the preparation of products that reduce the accumulation of advanced glycation end products.

2. The use according to claim 1, characterized in that The products that reduce the accumulation of advanced glycation end products include anti-glycation and / or anti-aging products.

3. The use according to any one of claims 1 to 2, characterized in that: The product for reducing accumulation of advanced glycation end products satisfies at least one of the following characteristics: (1) The product for reducing the accumulation of advanced glycation end products is a product for inhibiting the generation of advanced glycation end products; (2) The product for reducing the accumulation of advanced glycation end products is a product for reducing the generation of AGEs in the BSA-MGO reaction system; (3) The product for reducing the accumulation of advanced glycation end products is a product that inhibits the generation of AGEs in the increase of cellular AGEs induced by glucose; (4) The product for reducing the accumulation of advanced glycation end products is a product for reducing skin yellowing caused by the accumulation of AGEs; (5) The product for reducing the accumulation of advanced glycation end products is a product that exerts an anti-aging effect by reducing AGEs.

4. The use according to any one of claims 1 to 2, characterized in that: The product for reducing accumulation of advanced glycation end products comprises at least one of cosmetics and food.

5. The use according to any one of claims 1 to 2, characterized in that: The product can be used orally or topically.

6. The use according to any one of claims 1 to 2, characterized in that: The dosage forms of the product include solid dosage forms, semi-solid dosage forms and liquid dosage forms.

7. The use according to claim 6, characterized in that The dosage form of the product is a liquid dosage form.

8. The use according to claim 6, characterized in that The solid dosage forms include tablets, capsules, pills or granules; the semisolid dosage forms include ointments, gel pastes or patches; the liquid dosage forms include solutions, syrups, emulsions or tinctures.

9. A product for reducing accumulation of advanced glycation end products, characterized in that Includes tuberculous simple leaf rutin; Optionally, the product for reducing accumulation of advanced glycation end products further comprises auxiliary materials.

10. An anti-glycation and / or anti-aging product, characterized in that: Includes tuberculous simple leaf rutin; Optionally, the anti-glycation and / or anti-aging product further comprises auxiliary materials.

Images